Prostate-specific antigen value as a marker in breast cancer

Area of Science:

• Oncology
• Immunohistochemistry
• Breast Cancer Research

Background:

• Prostate-specific antigen (PSA) immunoexpression is established in breast cancers.
• The prognostic value of extra-prostate PSA in breast carcinoma remains poorly understood.
• This study investigates PSA's role alongside established breast cancer prognostic markers.

Purpose of the Study:

• To evaluate PSA expression in breast carcinomas.
• To compare PSA results with prognostic markers: ER, PR, HER2/neu status, tumor type, grade, stage, size, nodal status, and menopausal status.
• To determine PSA's independent prognostic value in breast cancer.

Main Methods:

• Immunohistochemical assessment of PSA, ER, PR, and HER2/neu in 53 breast carcinoma cases.
• Chi-square test used to analyze relationships between PSA and clinical/histopathological markers.

Main Results:

• PSA was expressed in 60.3% of breast cancer cases.
• Significant correlation found between PSA expression and histological type and HER2/neu negative status in premenopausal women.
• No significant association between PSA positivity and menopausal status, nodal status, ER/PR status, HER2/neu status in postmenopausal patients, tumor size, or histological grade.

Conclusions:

• PSA is not a valuable independent prognostic factor in breast carcinoma.
• PSA positivity in a subset of breast cancers (small size, early stage, HER2/neu negative, ER/PR positive) may indicate a better prognosis.
• PSA could be a useful marker for identifying breast cancer subsets that may respond to endocrine therapy, when used with other prognostic markers.